Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD and Food-Effect Study of TBI-223 in Healthy Subjects
NCT04865536Phase 1Completed
- Sponsor
- TB Alliance
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TBI-223 in Tuberculosis (TB) (3 arms), sponsored by TB Alliance. Primary endpoints: Safety assessment Vital Signs (BP, PR, RR, Temp, Pulse Oximetry) at 12 weeks, Safety assessment - Cardiac monitoring at 12 weeks and 6 more. Started Feb 2021; status: completed.
02
Drugs
TBI-223
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04865536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04865536.